RNA specialist Ribo files $205m IPO in Hong Kong Chinese RNA-based medicine developer Ribo has filed a Hong Kong IPO to raise cash for its siRNA drug for thrombotic diseases.

Chinese #RNA-based medicine developer Suzhou #Ribo Life Science has filed a #HongKong #IPO, aiming to raise new funds for its lead RBD4059 drug candidate for #thromboticdiseases.